Exploring the Real-World Treatment Landscape of mNSCLC

Metastatic non-small cell lung cancer (mNSCLC) remains a major challenge worldwide. The introduction of immune checkpoint inhibitors (ICIs) has transformed treatment, but their real-world impact varies across healthcare systems with different treatment practices and reimbursement strategies. A deeper understanding of these variations and their clinical implications is essential to improving patient outcomes and informing clinical guidelines.

The iCAN mNSCLC Studyathon brings together researchers, clinicians, and data experts globally to systematically analyze real-world patient data in a privacy-preserving, federated manner by virtue of the OMOP common data model. Utilizing the OHDSI community-driven, standardized and open source methodologies, we can study treatment patterns and outcomes across diverse healthcare settings in a way that ensures findings are reliable, transparent, and globally impactful.

This collaborative approach allows us to compare variations across countries, leading to better, data-driven insights that can shape clinical practice, influence policy, and ultimately improve care for mNSCLC patients worldwide.

In the four-day in-person studyathon, we will characterize real-world treatment patterns of metastatic NSCLC, with a focus on the adoption and impact of immune checkpoint inhibitors (ICIs) across different regions.

🔗 Study GitHub Repository: https://github.com/ohdsi-studies/MNSCLCStudyathon

 If you’re interested in contributing, please reach out:
📧 Asieh Golozar – golozar@ohdsi.org
📧 Kimmo Porkka – kimmo.porkka@helsinki.fi
📧 Eric Fey – eric.fey@hus.fi

iCAN-LUNG representatives: Heidi Haikala, Ilkka Ilonen
HUS representatives: Aija Knuuttila, Paula Kauppi, Ilkka Ilonen

Watch this space for updates!